Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials

Itai Danovitch, Kyla Truman, Haze Brown, Macie Miller, Shaishav Shah, Jayant Totlani, Daniel N. Kaidbay, Kaleab K. Tessema, Zholi Minasyan, Waguih William IsHak, Samuel Miles, Robert N. Pechnick

Open source

DOI
10.1007/s40263-026-01334-4
Published
2026-09-23
Container
CNS Drugs
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40263-026-01334-4,
  title = {Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials},
  author = {Itai Danovitch and Kyla Truman and Haze Brown and Macie Miller and Shaishav Shah and Jayant Totlani and Daniel N. Kaidbay and Kaleab K. Tessema and Zholi Minasyan and Waguih William IsHak and Samuel Miles and Robert N. Pechnick},
  year = {2026},
  journal = {CNS Drugs},
  doi = {10.1007/s40263-026-01334-4},
  url = {https://doi.org/10.1007/s40263-026-01334-4}
}

RIS

TY  - JOUR
TI  - Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials
AU  - Itai Danovitch
AU  - Kyla Truman
AU  - Haze Brown
AU  - Macie Miller
AU  - Shaishav Shah
AU  - Jayant Totlani
AU  - Daniel N. Kaidbay
AU  - Kaleab K. Tessema
AU  - Zholi Minasyan
AU  - Waguih William IsHak
AU  - Samuel Miles
AU  - Robert N. Pechnick
PY  - 2026
JO  - CNS Drugs
DO  - 10.1007/s40263-026-01334-4
UR  - https://doi.org/10.1007/s40263-026-01334-4
ER  - 

APA

Danovitch, I., Truman, K., Brown, H., Miller, M., Shah, S., Totlani, J., Kaidbay, D. N., Tessema, K. K., Minasyan, Z., IsHak, W. W., Miles, S., & Pechnick, R. N. (2026). Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials. CNS Drugs. https://doi.org/10.1007/s40263-026-01334-4

Source records